ENDRA Life Sciences (NDRA) Cash from Financing Activities (2016 - 2026)
ENDRA Life Sciences (NDRA) posted quarterly Cash from Financing Activities of $263747.0 for Q1 2026, up 80.89% year-over-year from $145803.0 in Q1 2025, and down 94.24% quarter-over-quarter from $4.6 million in Q4 2025.
ENDRA Life Sciences (NDRA) Cash from Financing Activities (2016 - 2026) Analysis & Trends
ENDRA Life Sciences (NDRA) has reported Cash from Financing Activities for 11 consecutive years, with $263747.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 80.89% year-over-year to $263747.0; the TTM figure through Mar 2026 stood at $5.9 million (down 21.84% YoY), while the FY2025 annual figure was $5.7 million, down 26.59% from the prior year.
- Cash from Financing Activities slipped to $263747.0 in Q1 2026 per NDRA's latest filing, from $4.6 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $7.5 million in Q2 2022 and bottomed at $1683.0 in Q3 2024.
- Historically, Cash from Financing Activities has averaged $2.3 million across 5 years, with a median of $857415.0 in 2025.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities plunged 99.85% — and 2025, when it surged 8780.93%.
- ENDRA Life Sciences' Cash from Financing Activities stood at $7.5 million in 2022, then sank by 77.85% to $1.7 million in 2023, then plunged by 99.9% to $1683.0 in 2024, then surged by 272035.41% to $4.6 million in 2025, then slumped by 94.24% to $263747.0 in 2026.
- Business Quant data shows NDRA's Cash from Financing Activities at $263747.0 in Q1 2026, $4.6 million in Q4 2025, and $149466.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn | -1.57 Bn |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn | 7.27 Bn |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn | 12.21 Mn |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn | -144.00 Mn |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn | -214.00 Mn |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn | -325.19 Mn |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn | -129.00 Mn |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn | -317.75 Mn |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn | -919.90 Mn |
| 10 | ENDRA Life Sciences | 7.16 Mn | 1.62 Mn | - | 3.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.89 Mn |
| Jun 30, 2026 | 3.89 Mn |
| Mar 31, 2026 | 263,747.00 |
| Mar 31, 2026 | 263,747.00 |
| Dec 31, 2025 | 4.58 Mn |
| Dec 31, 2025 | 4.58 Mn |
| Sep 30, 2025 | 149,466.00 |
| Sep 30, 2025 | 149,466.00 |
| Jun 30, 2025 | 857,415.00 |
| Jun 30, 2025 | 857,415.00 |
| Mar 31, 2025 | 145,803.00 |
| Mar 31, 2025 | 145,803.00 |
| Sep 30, 2024 | 1,683.00 |
| Sep 30, 2024 | 1,683.00 |
| Jun 30, 2024 | 7.34 Mn |
| Jun 30, 2024 | 7.34 Mn |
| Mar 31, 2024 | 468,902.00 |
| Mar 31, 2024 | 468,902.00 |
| Dec 31, 2023 | 1.67 Mn |
| Dec 31, 2023 | 1.67 Mn |